Targeting FLT3 as therapy for leukemia.

被引：0
|
作者：
Small, D [1 ]
Levis, M [1 ]
Smith, D [1 ]
Zheng, R [1 ]
Allebach, J [1 ]
Chen, P [1 ]
Kim, KT [1 ]
Li, L [1 ]
Ahn, J [1 ]
Brown, P [1 ]
Piloto, O [1 ]
Perl, A [1 ]
机构：
[1] Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA
来源：
CLINICAL CANCER RESEARCH | 2003年 / 9卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6268S / 6269S
页数：2
相关论文
共 50 条
  • [41] Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
    Abhishek Maiti
    Courtney D. DiNardo
    Naval G. Daver
    Caitlin R. Rausch
    Farhad Ravandi
    Tapan M. Kadia
    Naveen Pemmaraju
    Gautam Borthakur
    Prithviraj Bose
    Ghayas C. Issa
    Nicholas J. Short
    Musa Yilmaz
    Guillermo Montalban-Bravo
    Alessandra Ferrajoli
    Elias J. Jabbour
    Nitin Jain
    Maro Ohanian
    Koichi Takahashi
    Philip A. Thompson
    Sanam Loghavi
    Kathryn S. Montalbano
    Sherry Pierce
    William G. Wierda
    Hagop M. Kantarjian
    Marina Y. Konopleva
    Blood Cancer Journal, 11
  • [42] The Future of Targeting FLT3 Activation in AML
    Leick, Mark B.
    Levis, Mark J.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2017, 12 (03) : 153 - 167
  • [43] The Future of Targeting FLT3 Activation in AML
    Mark B. Leick
    Mark J. Levis
    Current Hematologic Malignancy Reports, 2017, 12 : 153 - 167
  • [44] Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
    Maiti, Abhishek
    DiNardo, Courtney D.
    Daver, Naval G.
    Rausch, Caitlin R.
    Ravandi, Farhad
    Kadia, Tapan M.
    Pemmaraju, Naveen
    Borthakur, Gautam
    Bose, Prithviraj
    Issa, Ghayas C.
    Short, Nicholas J.
    Yilmaz, Musa
    Montalban-Bravo, Guillermo
    Ferrajoli, Alessandra
    Jabbour, Elias J.
    Jain, Nitin
    Ohanian, Maro
    Takahashi, Koichi
    Thompson, Philip A.
    Loghavi, Sanam
    Montalbano, Kathryn S.
    Pierce, Sherry
    Wierda, William G.
    Kantarjian, Hagop M.
    Konopleva, Marina Y.
    BLOOD CANCER JOURNAL, 2021, 11 (02)
  • [45] Targeting FLT3 Mutation in Acute Myeloid Leukemia: Current Strategies and Future Directions
    Fedorov, Kateryna
    Maiti, Abhishek
    Konopleva, Marina
    CANCERS, 2023, 15 (08)
  • [46] Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches
    Tecik, Melisa
    Adan, Aysun
    ONCOTARGETS AND THERAPY, 2022, 15 : 1449 - 1478
  • [47] Targeting FLT3 in MLL gene rearranged infant Acute Lymphoblastic Leukemia (ALL).
    Stam, RW
    den Boer, ML
    Armstrong, SA
    Sallen, SE
    Kazemier, KM
    Pieters, R
    BLOOD, 2003, 102 (11) : 224A - 224A
  • [48] Survey of Activated FLT3 Signaling in Leukemia
    Gu, Ting-lei
    Nardone, Julie
    Wang, Yi
    Loriaux, Marc
    Villen, Judit
    Beausoleil, Sean
    Tucker, Meghan
    Kornhauser, Jon
    Ren, Jianmin
    MacNeill, Joan
    Gygi, Steven P.
    Druker, Brian J.
    Heinrich, Michael C.
    Rush, John
    Polakiewicz, Roberto D.
    PLOS ONE, 2011, 6 (04):
  • [49] Rational for targeting the hedgehog signalling pathway in acute myeloid leukemia with FLT3 mutation
    Bouscary, Didier
    ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4
  • [50] Effects of the FLT3 inhibitor PKC 412 in combination with cytostatic drugs in vitro in acute myeloid leukemia.
    Möllgård, L
    Bengtzen, S
    Fioretos, T
    Andersson, A
    Paul, C
    Lehmann, S
    BLOOD, 2004, 104 (11) : 501A - 501A
12345